Novel Nitrogen Heterocycle-Hydroxamic Acid Conjugates Demonstrating Potent Anti-Acute Lymphoblastic Leukemia Activity: Induction of Endogenous Apoptosis and G0/G1 Arrest via Regulation of Histone H3 Acetylation and AKT Phosphorylation in Jurkat Cells.

Lingjie Wu, Li Zhao, Liping Wang, Yi Lu, Gaojie Lou, Bin Zhang, Ning Wang

Abstract read

In one paragraph

Article in Cells, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Lingjie WuSchool of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China.

Li ZhaoInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.

Liping WangInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.

Yi LuSchool of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China.

Gaojie LouSchool of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China.

Bin ZhangSchool of Pharmacy, Health Science Center, Ningbo University, Ningbo 315211, China.ORCID 0000-0002-4371-4746

Ning WangInstitute of Drug Discovery Technology, Ningbo University, Ningbo 315211, China.ORCID 0000-0002-5625-5358

Funding

the Science and Technology Plan Project of Ningbo City 2022S128the Science and Technology Plan Project of Ningbo City 2023S048Zhejiang Provincial Department of Education Y202456631

6 · The paper itself

Abstract

Epigenetics garnered significant scientific interest in recent decades, with histone acetylation emerging as the most prevalent epigenetic deregulation process observed in malignancies. The clinical application of histone deacetylase (HDAC) inhibitors faced challenges, including complex therapeutic mechanisms and inconsistent treatment outcomes. In Acute Lymphoblastic Leukemia (ALL), the dysregulation of HDAC activity presents a promising therapeutic target. To investigate cellular-level tumor suppression by HDAC inhibitors possessing potent target engagement, we developed two novel azetidine-hydroxamic acid conjugates. Compared to N-hydroxy-4-((quinolin-4-ylamino)methyl)benzamide (NBU-1), N-hydroxy-6-((5-methyl-4-nitro-9-oxo-9,10-dihydroacridin-1-yl)amino)hexanamide (NBU-2) demonstrated enhanced inhibitory activity against HDAC1 (class I) and HDAC6 (class II) with IC

Indexed as

Antineoplastic AgentsApoptosisG1 Phase Cell Cycle CheckpointsHistonesHydroxamic AcidsNitrogenPrecursor Cell Lymphoblastic Leukemia-LymphomaProto-Oncogene Proteins c-aktResting Phase, Cell CycleAcetylationCell ProliferationHistone Deacetylase InhibitorsHumansJurkat CellsPhosphorylationAntineoplastic AgentsHistone Deacetylase InhibitorsHistonesHydroxamic AcidsNitrogenProto-Oncogene Proteins c-aktanti-cancer mechanismapoptosiscell cycle arresthistone deacetylaseinhibitorproteomics

Identifiers

PMID41294878

DOI10.3390/cells14221822

PMCPMC12651750

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.